6 Best Peptides for Constipation

What to Know Before Choosing a Peptide for Constipation

The peptide landscape for constipation is unusually varied. At one end sits a pair of FDA-approved prescription drugs backed by large randomized controlled trials involving more than a thousand patients. At the other end sit gut-repair compounds that have never been tested in a constipation-specific human trial but appear regularly in functional medicine protocols and community discussion. A few compounds fall somewhere between those poles, with early clinical investigation underway or with mechanistic rationale that practitioners find compelling even where controlled data is thin.

Every compound in this guide earned its place by the same criterion: people use it, or are actively discussing using it, for constipation relief. FDA approval, telemedicine availability, and research-chemical status are all equally eligible under that test. Evidence strength is stated honestly inside each entry rather than used as a filter at the door.

The entries are numbered by how prominently each compound appears in research and documented real-world use, not as a ranking of one being better than another. Number one is not a recommendation and number six is not a consolation. The right choice depends on your specific situation, which is exactly what the app is built to work through with you.

One note before diving in: several well-known peptide medications, particularly the GLP-1 receptor agonists used for weight loss and blood sugar control, actually cause constipation as a side effect rather than relieve it. This article covers peptides used to relieve constipation. That distinction is worth keeping in mind if you are currently on one of those medications and looking for options.

1. Linaclotide: The FDA-Approved Standard for Chronic Constipation

Linaclotide is a 14-amino acid synthetic peptide and the most extensively studied pharmaceutical option for chronic constipation. Sold under the brand name Linzess, it has been FDA-approved since 2012 for chronic idiopathic constipation and IBS with constipation in adults, with a pediatric approval for functional constipation in children aged 6 to 17 added in 2024. Among peptides used for this condition, it carries the deepest evidence base by a wide margin.

The mechanism is precise and well-characterized. Linaclotide binds to guanylate cyclase-C receptors on the inner surface of intestinal epithelial cells. That binding triggers a cellular signaling process that raises levels of cyclic guanosine monophosphate, a chemical messenger that then activates chloride channels in the intestinal lining. Those channels push chloride and bicarbonate ions into the intestinal space, which draws water in by osmosis. The result is softer stool and faster transit. Some of that cyclic GMP also leaks outside the cells and appears to reduce the sensitivity of nearby pain-signaling nerves, which explains why linaclotide reduces abdominal pain in IBS-C patients alongside its bowel effects.

The human trial data is robust. A dose-ranging study in 310 patients with chronic constipation found that all tested doses produced meaningful increases in weekly bowel movement frequency compared to placebo, with gains of roughly 2.6 to 4.3 additional movements per week versus about 1.5 for placebo. Two subsequent Phase 3 randomized controlled trials enrolled 1,276 patients combined and confirmed the benefit: between 16 and 21 percent of linaclotide patients met the primary efficacy endpoint, compared to 3 to 6 percent of placebo patients. Those numbers are the foundation for its approval.

The main side effect is diarrhea, which is dose-dependent and the primary reason patients discontinue the medication. A boxed warning exists for use in children under 6 due to risk of serious dehydration. Linaclotide is available by prescription through standard pharmacies and telemedicine platforms that conduct a clinical evaluation.

2. Plecanatide: The Second FDA-Approved Option, Structurally Distinct

Plecanatide works through the same guanylate cyclase-C receptor pathway as linaclotide and was FDA-approved in January 2017 for chronic idiopathic constipation and IBS with constipation in adults. It is sold under the brand name Trulance. What separates it mechanistically is its structural origin: plecanatide is an analog of uroguanylin, a hormone naturally produced by the intestine that activates the same receptor. Because it mirrors a molecule the gut already makes, some researchers describe its action as more physiologically native.

The structural similarity to uroguanylin gives plecanatide a pH-sensitive activation profile. It activates preferentially in the slightly acidic environment of the proximal small intestine, where uroguanylin itself is most active. Whether that pH sensitivity translates into a meaningfully different side effect profile compared to linaclotide varies from patient to patient. The primary adverse effect for plecanatide, as with linaclotide, is diarrhea.

Plecanatide carries the same class-wide boxed warning against use in children under 6 years of age. Its approval is currently limited to adults, without the pediatric extension linaclotide received in 2024. Like linaclotide, it requires a prescription and is available through licensed prescribers and standard pharmacy channels.

For most people choosing between the two FDA-approved options, the practical differences are modest. Both operate through the same mechanism, both carry similar safety profiles, and the choice often comes down to insurance coverage, prior authorization status, or prescriber preference rather than a meaningful pharmacological distinction.

3. BPC-157: For Gut-Lining Repair When the Cause May Be Structural

BPC-157 stands for Body Protection Compound-157. It is a 15-amino acid synthetic peptide derived from a sequence found in human gastric juice protein, and it appears consistently in functional medicine gut-health circles and in community discussions about digestive problems. It is not FDA-approved for any condition, has no published human clinical trial data for constipation, and sits firmly in the research-peptide category. It belongs on this list because it is a real part of the conversation around gut health and constipation in peptide communities and functional medicine practice.

BPC-157 does not act on constipation the way linaclotide does. There is no direct stimulation of secretory pathways that a pharmacologist would point to for constipation relief. The proposed mechanism is indirect and runs through gut-repair channels. Animal research has found that BPC-157 accelerates healing of damaged intestinal epithelium, reduces inflammation in gut tissue, and improves microcirculation, the fine blood supply to the intestinal wall. The reasoning in functional medicine is that constipation caused or worsened by gut inflammation, tissue damage, or poor intestinal barrier integrity might improve when those underlying conditions are addressed. Whether that reasoning translates to meaningful constipation relief in humans has not been tested in a controlled setting.

The animal research on gut healing is genuine and reasonably consistent across multiple studies. The gap between that preclinical foundation and demonstrated human constipation relief is large, and honesty requires saying so. On the human side, what exists is a small number of anecdotal reports. At least one community account describes a person with pelvic floor dysfunction who reported notable improvement in bowel function after using BPC-157, though that case involved a specific structural condition rather than idiopathic constipation and cannot be generalized.

BPC-157 is available as a research chemical and appears in functional medicine gut protocols, often alongside other gut-support compounds. It is not legally administered for therapeutic purposes without an appropriate clinical framework, and its long-term safety in humans has not been established. The American Medical Association has raised concerns about injectable peptides sold for gut health purposes through unregulated channels. Anyone exploring it is working in territory where risks are meaningfully less well-characterized than with the approved options.

4. Larazotide Acetate: For Constipation Linked to Gut Barrier Dysfunction

Larazotide acetate is an investigational peptide whose primary studied mechanism is restoration of intestinal tight junctions, the molecular seals between gut epithelial cells that maintain the intestinal barrier. When those tight junctions break down, the gut becomes more permeable, a condition commonly called leaky gut, which can drive chronic inflammation and disrupt normal digestive function including motility. Larazotide works by counteracting zonulin-mediated tight junction disruption, one of the identified pathways through which barrier integrity is lost.

The connection to constipation is mechanistic and indirect. If gut barrier dysfunction is contributing to the inflammatory environment that impairs normal bowel transit, repairing that barrier may help restore more normal motility and secretory function. Larazotide has been studied in clinical settings for conditions involving gut barrier disruption, most notably celiac disease, and the early-stage human data on barrier restoration is genuine. Whether that translates to constipation relief specifically has not been tested in a constipation-focused clinical trial.

In functional medicine contexts, larazotide appears alongside BPC-157 and other gut-support compounds in protocols framed around healing the intestinal environment rather than directly stimulating motility. It is not FDA-approved for any gastrointestinal condition but is available through some functional medicine and compounding pharmacy channels. For constipation specifically, the evidence base is preclinical and mechanistic rather than established in controlled human studies.

5. KPV: For Inflammation-Driven Motility Disruption

KPV is a tripeptide composed of three amino acids: lysine, proline, and valine. It is derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone and has been studied primarily for its anti-inflammatory effects in gut tissue. Its presence in constipation discussions is not based on direct evidence for constipation relief. It appears in functional medicine gut protocols as an anti-inflammatory component, with the rationale that reducing gut inflammation may allow normal motility patterns to re-establish themselves when inflammation is the underlying driver.

No human clinical trial data has been published for KPV and constipation as of 2026. What exists is animal research demonstrating anti-inflammatory effects in models of intestinal inflammation, alongside practitioner reports of its use in combination gut-health protocols. KPV is commonly included in what some functional medicine practitioners call gut peptide stacks, pairing it with BPC-157, larazotide, and other compounds in an attempt to address multiple aspects of gut dysfunction simultaneously.

The evidence here is preclinical and mechanism-based. KPV earns its place on this list because it appears in real-world gut-health protocols and in community discussions about peptides for digestive issues, not because a controlled trial has established it as a constipation treatment. Anyone using it is doing so as part of a broader functional medicine approach, and the evidence supporting that approach for constipation is experiential rather than clinical.

6. Tributyrin: The Butyrate-Delivery Compound in Gut-Health Protocols

Tributyrin is not a peptide in the traditional sense. It is a triglyceride ester of butyric acid, a short-chain fatty acid that gut bacteria produce naturally when they ferment dietary fiber. When tributyrin is metabolized, it delivers butyrate to the colon. That delivery is its entire function, and it is why tributyrin appears alongside compounds like BPC-157 and larazotide in gut-health discussions rather than alongside the peptide drugs that directly target motility.

Butyrate matters to the colon for two reasons that connect to constipation. First, it is the primary fuel source for colonocytes, the cells lining the colon wall, and maintaining healthy colonocytes supports normal epithelial function and barrier integrity. Second, butyrate has been shown in research to influence colonic smooth muscle contractions and peristaltic activity, the wave-like movements that push stool forward. It also suppresses certain inflammatory signaling pathways in gut tissue, which may support more normal motility in a chronically inflamed environment.

The evidence for tributyrin and constipation specifically is limited. Most human research on butyrate and its precursors concerns inflammatory bowel conditions, colorectal health, and gut microbiome support rather than chronic idiopathic constipation as a primary endpoint. The mechanistic rationale is plausible and grounded in real biology, but constipation-specific clinical trial data does not exist for tributyrin. It is available over the counter as a dietary supplement, requires no prescription, and is generally well-tolerated, with GI discomfort at higher amounts being the most commonly noted side effect.

It appears in this guide because functional medicine practitioners consistently include it in gut-repair frameworks alongside peptides, and community discussions of gut-health protocols regularly name it when constipation is the concern. The evidence sits at the supplement and mechanistic tier rather than the clinical trial tier.

How These Peptides Compare

Frequently Asked Questions

Are the peptides in this guide legal to use for constipation?

Linaclotide and plecanatide are FDA-approved prescription medications that are legal to use under the care of a licensed prescriber, including through telemedicine platforms that conduct a clinical evaluation. BPC-157, larazotide acetate, and KPV are research compounds, legal to purchase in most jurisdictions for research use but not legally approved for human therapeutic use without an appropriate clinical framework. Tributyrin is sold legally as an over-the-counter dietary supplement and requires no prescription.

How quickly do these compounds typically produce results?

The FDA-approved options have well-characterized timelines from clinical trials. In the linaclotide Phase 3 trials, improvements in bowel movement frequency appeared within the first one to two weeks and continued through the full 12-week study period. For research-stage compounds like BPC-157 and larazotide, no clinical timeline has been established for constipation because no constipation-focused human trial has been conducted. Community reports on those compounds vary widely, and any timeline discussed for non-approved peptides is experiential rather than clinically established.

Can peptides help with constipation caused by GLP-1 medications?

GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and gut transit as a mechanism-related effect, and constipation affects a meaningful portion of people using them. The FDA-approved guanylate cyclase-C agonists covered in this guide work through a completely separate pathway and are not contraindicated alongside GLP-1 medications, but whether they are the right intervention for any individual depends on circumstances that require clinical evaluation. Some functional medicine practitioners also incorporate gut-repair peptides into protocols for people experiencing GI side effects on GLP-1 therapies, though that approach is based on clinical judgment rather than controlled evidence specific to that combination.

Do these compounds require injections?

Linaclotide and plecanatide are taken orally as capsules and are not absorbed into the bloodstream, so no injection is involved. BPC-157 is most often used via subcutaneous injection in research and functional medicine contexts, though some practitioners also work with oral formats. Larazotide and KPV have been studied and used in oral formats as well. Tributyrin is an oral supplement available in capsule or softgel form. Delivery method is one of the practical considerations worth discussing with a healthcare provider when evaluating options.

Is a prescription required for any of these?

Yes, for two of them. Linaclotide and plecanatide are prescription-only medications available through licensed prescribers and standard pharmacies. The remaining four compounds in this guide do not require a prescription to obtain, though the research peptides among them sit in regulatory territory where legitimate human therapeutic use still requires clinical oversight, and tributyrin is simply an over-the-counter supplement.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for constipation in one place.